With box warnings

Without box warnings

Branded

Generic

4 results

cerdelga
(eliglustat)
Genzyme Corporation
Usage: CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are categorized as extensive, intermediate, or poor CYP2D6 metabolizers, as determined by an FDA-cleared test. Limitations apply for ultra-rapid metabolizers and indeterminate genotypes.
miglustat
(MIGLUSTAT)
ANI Pharmaceuticals, Inc.
Usage: Miglustat is indicated as monotherapy for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.
yargesa
(Miglustat)
Edenbridge Pharmaceuticals LLC.
Usage: YARGESA is indicated for the treatment of adult patients with mild to moderate Type 1 Gaucher disease as monotherapy when enzyme replacement therapy is not suitable due to reasons such as allergy, hypersensitivity, or poor venous access.
zavesca
(miglustat)
Actelion Pharmaceuticals US, Inc.
Usage: ZAVESCA is indicated as monotherapy for treating adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.

Glucosylceramide Synthase Inhibitor class drugs

cerdelga